Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 27;21(17):6204.
doi: 10.3390/ijms21176204.

The Role of NLRP3 Inflammasome in the Pathogenesis of Traumatic Brain Injury

Affiliations
Review

The Role of NLRP3 Inflammasome in the Pathogenesis of Traumatic Brain Injury

Natasha Irrera et al. Int J Mol Sci. .

Abstract

Traumatic brain injury (TBI) represents an important problem of global health. The damage related to TBI is first due to the direct injury and then to a secondary phase in which neuroinflammation plays a key role. NLRP3 inflammasome is a component of the innate immune response and different diseases, such as neurodegenerative diseases, are characterized by NLRP3 activation. This review aims to describe NLRP3 inflammasome and the consequences related to its activation following TBI. NLRP3, caspase-1, IL-1β, and IL-18 are significantly upregulated after TBI, therefore, the use of nonspecific, but mostly specific NLRP3 inhibitors is useful to ameliorate the damage post-TBI characterized by neuroinflammation. Moreover, NLRP3 and the molecules associated with its activation may be considered as biomarkers and predictive factors for other neurodegenerative diseases consequent to TBI. Complications such as continuous stimuli or viral infections, such as the SARS-CoV-2 infection, may worsen the prognosis of TBI, altering the immune response and increasing the neuroinflammatory processes related to NLRP3, whose activation occurs both in TBI and in SARS-CoV-2 infection. This review points out the role of NLRP3 in TBI and highlights the hypothesis that NLRP3 may be considered as a potential therapeutic target for the management of neuroinflammation in TBI.

Keywords: NLRP3 inflammasome; SARS-CoV-2; neuroinflammation; pyroptosis; traumatic brain injury.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
TBI (Traumatic brain injury) activates different processes such as edema, oxidative stress, cell death mechanisms and inflammation. In the secondary phase, neuroinflammation plays a key role and different proinflammatory cytokines are released such as TNF-α (Tumor Necrosis Factor alpha), (interleukin) IL-6, IL-1β and last, but not least (NOD-, LRR- and pyrin domain-containing 3) NLRP3 inflammasome is activated. NLRP3 inflammasome stimulation mediates the release of caspase-1, IL-1β and IL-18. Moreover, NLRP3 activates the pyroptosis as a mechanism of cell death.

Similar articles

Cited by

References

    1. Carney N., Totten A.M., O’Reilly C., Ullman J.S., Hawryluk G.W., Bell M.J., Bratton S.L., Chesnut R., Harris O.A., Kissoon N., et al. Guidelines for the management of severe traumatic brain injury. Neurosurgery. 2017;80:6–15. doi: 10.1227/NEU.0000000000001432. - DOI - PubMed
    1. Cruz-Haces M., Tang J., Acosta G., Fernandez J., Shi R. Pathological correlations between traumatic brain injury and chronic neurodegenerative diseases. Transl. Neurodegener. 2017;6:20. doi: 10.1186/s40035-017-0088-2. - DOI - PMC - PubMed
    1. Bonsack B., Corey S., Shear A., Heyck M., Cozene B., Sadanandan N., Zhang H., Gonzales-Portillo B., Sheyner M., Borlongan C.V. Mesenchymal stem cell therapy alleviates the neuroinflammation associated with acquired brain injury. CNS Neurosci. Ther. 2020;26:603–615. doi: 10.1111/cns.13378. - DOI - PMC - PubMed
    1. Teasdale G., Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974;2:81–84. doi: 10.1016/S0140-6736(74)91639-0. - DOI - PubMed
    1. Jellinger K.A. Traumatic brain injury as a risk factor for Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry. 2004;75:511–512. - PMC - PubMed

MeSH terms